Evidence map›Paper›PMID 35262018›Full record

ArticleJournal of clinical virology plus2021

Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer.

Daniele Focosi, Alfredo Rosellini, Pietro Giorgio Spezia, Lisa Macera, Maria Lanza, Aldo Paolicchi, Denise Biagini, Andreina Baj, Mauro Pistello, Fabrizio Maggi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Daniele FocosiNorth-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Alfredo RoselliniDivision of Virology, Pisa University Hospital, Italy.
Pietro Giorgio SpeziaDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Lisa MaceraDivision of Virology, Pisa University Hospital, Italy.
Maria LanzaNorth-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Aldo PaolicchiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Denise BiaginiDepartment of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy.
Andreina BajDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Mauro PistelloDivision of Virology, Pisa University Hospital, Italy.
Fabrizio MaggiDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
University of Pisa · ITAziende Socio Sanitarie Territoriale dei Sette LaghiUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several ABO blood groups have been associated with the likelihood of infection, severity, and/or outcome of COVID-19 in hospitalized cohorts, raising the hypothesis that anti-A isoagglutinins in non-A-group recipients could act as neutralizing antibodies against SARS-CoV-2. Materials and methods: We run live virus neutralization tests using sera from 58 SARS-CoV-2 seronegative blood donors (27 O-group and 31 A-group) negatives for SARS-CoV-2 IgG to investigate what degree of neutralizing activity could be detected in their sera and eventual correlation with anti-A isoagglutinin titers. Results: We could not find clinically relevant neutralizing activity in any blood group, regardless of anti-isoagglutinin titer. Discussion: Our findings suggest that mechanisms other than neutralization explain the differences in outcomes from COVID19 seen in different ABO blood groups.

Indexed as

ABO blood groupAnti-A isoagglutininsConvalescent plasmaCOVID-19Neutralizing antibodySARS-CoV-2

Identifiers

PMID35262018
PMCPMC8349435
OpenAlexW3193804859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.